Skip to main
CYRX

CryoPort (CYRX) Stock Forecast & Price Target

CryoPort (CYRX) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 56%
Buy 33%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

CryoPort Inc. is positioned for growth as the demand for cell and gene therapies continues to rise, leading to expectations of increased commercial revenue and clinical trial activity driven by advancements in oncology and rare diseases. In the most recent quarter, the company's total revenue reached $44 million, demonstrating a 15% year-over-year growth on a constant currency basis, slightly up from 14% in the previous quarter. The ongoing upward trajectory in the number of approved therapies and those in development signals a robust pipeline, reinforcing a favorable outlook for CryoPort in the life sciences market.

Bears say

CryoPort Inc. is experiencing a decline in momentum, as evidenced by its Life Sciences Services revenue growth of 16%, which has decreased from 21% in the previous quarter. The adjusted EBITDA margin remains negative at (1.5%), reflecting challenges in profitability and performing below consensus expectations. Additionally, the company faces a bear case scenario driven by slower revenue growth linked to fewer approvals in the cell and gene therapy space, compounded by reduced demand for MVE freezers, leading to lowered earnings projections for 2026.

CryoPort (CYRX) has been analyzed by 9 analysts, with a consensus rating of Buy. 56% of analysts recommend a Strong Buy, 33% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CryoPort and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CryoPort (CYRX) Forecast

Analysts have given CryoPort (CYRX) a Buy based on their latest research and market trends.

According to 9 analysts, CryoPort (CYRX) has a Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CryoPort (CYRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.